期刊
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
卷 23, 期 3, 页码 505-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.soc.2014.03.006
关键词
Breast cancer; Neoadjuvant chemotherapy; Preoperative chemotherapy; Pathologic complete response
资金
- NCI NIH HHS [P30 CA016672] Funding Source: Medline
Neoadjuvant systemic therapy in breast cancer treatment was initially utilized for inoperable disease. However, several randomized prospective studies have demonstrated comparable survival with adjuvant chemotherapy in early-stage, operable breast cancer while also decreasing tumor size facilitating breast conservation without significant increases in local recurrence. Response to therapy can predict outcome, with improved survival associated with pathologic complete response (pCR). Triple negative and HER2-positive subtypes show increased pCR rates. A multidisciplinary approach is necessary with neoadjuvant treatment. This can improve rates of breast conservation, provide insights into tumor biology and predict patient outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据